Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma Ads (NQ: ASND )

154.97 USD -3.69 (-2.33%)
Official Closing Price Updated: 4:00 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ascendis Pharma Ads

< Previous 1 2 3 4 5 6 Next >
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
From GlobeNewswire News Releases
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team
Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private... 
From Business Wire News Releases
Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced today the... 
From PR Newswire
Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
From GlobeNewswire News Releases
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China
- TransCon ™ C-Type Natriuretic Peptide (CNP), an investigational once-weekly long-acting prodrug of CNP, is ready for Phase 2 Clinical Trial in China - 
From PR Newswire
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Planned Board Transition
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20
From GlobeNewswire News Releases
Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11
From GlobeNewswire News Releases
Human Growth Hormone Deficiency (GHD) Drugs Market : Facts, Figures and Analytical Insights 2020-2023
Harrisburg, NC -- (SBWIRE) -- 10/27/2020 -- The Human Growth Hormone Deficiency (GHD) Drugs Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry... 
From SBWire - Latest Press Releases
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon PTH in Adult Hypo
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in Japan
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2020
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting
From GlobeNewswire News Releases
Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at 22nd European Congress of Endocrinology
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Participation at the 2020 Wells Fargo Virtual Healthcare Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Reports Second Quarter 2020 Financial Results and Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward Trial
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 27
From GlobeNewswire News Releases
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.